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Abstract 1 
Objective: The aim was to study the stability of dry powder inhaler (DPI) formulations 2 
containing antibiotic with different preparation ways -carrier-based, carrier-free, and novel 3 
combined formulation - and thereby to compare their physicochemical and in vitro-in silico 4 
aerodynamical properties before and after storage. 5 
Significance: Presenting a novel combined technology in the field of DPI formulation including 6 
the carrier-based and carrier-free methods, it is the most important reason to introduce this 7 
stable formulation for the further development of DPIs. 8 
Methods: The structure, the residual solvent content, the interparticle interactions, the particle 9 
size distribution and the morphology of the samples were studied. The aerodynamic values were 10 
determined based on the Cascade Impactor in vitro lung model. We tested the in silico 11 
behaviour of the novel combined formulated samples before and during storage.  12 
Results: The physical measurements showed that the novel combined formulated sample was 13 
the most favourable. It was found that thanks to the formulation technique and the use of 14 
magnesium stearate have a beneficial effect on the stability compare with the carrier-based 15 
formulation without magnesium stearate and carrier-free formulations. The results of in vitro 16 
and in silico lung models were consistent with the physical results, so the highest deposition 17 
was found for the novel combined formulated sample during the storage. 18 
Conclusion: It can be established that after the storage a novel combined formulated DPI 19 
contained amorphous drug to have around 2.5 μm mass median aerodynamic diameter and 20 
nearly 50 % fine particle fraction predicted high lung deposition in silico also. 21 
Keywords: novel combined formulation, pulmonary drug delivery, ciprofloxacin 22 
hydrochloride, sodium stearate, magnesium stearate, in silico assessment, interparticle 23 
interactions 24 
1. Introduction 1 
Cystic fibrosis (CF) is an autosomal recessive hereditary disease, caused by mutations in the 2 
gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein 3 
[1,2]. Due to the mutation, ion transports are modified through the membrane of airway 4 
epithelial cells. As a result, the pH of the airway surface liquid is lowered, the mucus is 5 
concentrated, mucociliary clearance efficiency is decreased, and the inflammation causes 6 
mucin hypersecretion, which promotes bacterial infection [3–6]. “Polymicrobial” infection –7 
which is defined as an individual patient at a particular point of time infected with a number of 8 
different organisms – is characteristic of CF. The most typical bacteria are: Pseudomonas 9 
aeruginosa, Haemophilus influenzae and Burkholderia cepacia (Gram-negatives); 10 
Staphylococcus aureus (Gram-positive). Haemophilus influenzae and Staphylococcus aureus 11 
cause the early infections of CF respiratory tract, then Pseudomonas aeruginosa becomes the 12 
most significant pathogen in adulthood [7]. In CF more effective anti-infective and anti-13 
inflammatory treatments are required to control ongoing inflammation, tissue destruction, and 14 
exacerbations. Therefore the formulation of potent inhaled agents would offer significant 15 
benefits for the prevention and treatment of pulmonary bacterial infections. The key challenges 16 
of the therapy for airway inflammation, structural changes and mucociliary dysfunction are 17 
opportunities for novel inhaled drug formulations [8,9]. 18 
Ciprofloxacin hydrochloride is the hydrochloride salt form of ciprofloxacin. This drug is a 19 
second generation fluoroquinolone antibiotic, which is a fluorinated derivative of nalidixic acid 20 
[10,11]. Ciprofloxacin is effective against both Gram-positive and Gram-negative 21 
microorganisms. In point of its mechanism of action, the main target is the bacterial enzymes 22 
DNA gyrase (topoisomerase II) in Gram-negative bacteria and topoisomerase IV in Gram-23 
positive bacteria [12,13]. Therefore, it may be used for respiratory bacterial infections in 24 
patients with CF [14]. 25 
Drugs (e.g. antibiotics) can be delivered via the pulmonary route for the purpose of achieving 1 
local and systemic effects. This type of drug delivery has many advantages. For example, it 2 
should be noted that by circumventing the gastrointestinal tract, the drugs reach the Cmax value 3 
in the blood within approximately 1-3 minutes [15]. By avoiding the first-pass effect of the liver 4 
and the enzymatic inactivation of the gastrointestinal system as metabolic pathways, the use of 5 
lower doses of active agents is sufficient to induce the same therapeutic effect. Thus, the side 6 
effects profile could be modified. In addition, pulmonary drug delivery is a non-invasive 7 
therapeutic procedure, which does not cause pain or tissue damage [16,17]. However, at present 8 
only three inhaled antibiotics (tobramycin, aztreonam and colistimethate (sodium)) are on the 9 
market [18]. The use of the dry powder inhalers (DPIs) offers outstandingly many benefits: 10 
propellant-free, easy to use, portability, increased stability, less need for patient coordination, 11 
etc. [19–21]. 12 
The specialized literature fundamentally separates carrier-based, and carrier-free systems based 13 
on the formulation of DPI systems. Both formulations have advantages and disadvantages. Most 14 
of the DPIs available on the market are made with carrier-based formulation, which involves 15 
applying the active ingredient particles to the surface of a large carrier particle by forming an 16 
interactive physical mixture. The use of carriers is an advantage in the case of active ingredients 17 
that have a strong cohesive property, the flow properties of the composition are improved, 18 
applying of the small doses of the active substance could be easier by dilution with carrier, and 19 
the taste of the carrier confirms successful inhalation by the patient [22–24]. However, most of 20 
these compositions do not yet have outstanding lung deposition. These formulations have an 21 
average of 20-30 % fine particle fraction (FPF), meaning that the drug reaches the deeper layers 22 
of the lungs in a low percentage [25]. In the case of carrier-free DPI systems, the use of special 23 
excipients (e.g. L-leucine) and technologies (e.g. co-spray-drying) makes the application of a 24 
large carrier avoidable. Generally, these systems have low density and special morphology. 25 
However, they have around 50-60 % FPF results due to the apparent high cohesive properties 1 
between the active ingredient’s particles [26,27]. Many publications deal with the development 2 
of DPI containing ciprofloxacin or ciprofloxacin hydrochloride [12,28–33]. A serious challenge 3 
of our previous work was using the benefits of these two formulations (applying 1:10 ratio and 4 
current inhaled antibiotics are ~100 mg), the novel combined formulation (a co-spray-dried 5 
drug blended with surface modified lactose) produced by us resulted in a higher FPF value than 6 
the carrier-based and carrier-free DPI formulations [18]. 7 
The aim of the present work was – on the basis of the aforementioned publication [18] – the 8 
stability testing of the carrier-based formulation; carrier-free formulation and novel combined 9 
formulation DPI systems, which contain ciprofloxacin hydrochloride. Before and after the 10 
storage we investigated the morphology, particle size and structure changes of prepared 11 
formulations, as well as the modification of interparticle interactions, and mainly how these 12 
physical changes influence the in vitro aerodynamic parameters. Furthermore, our aim was to 13 
carry out computer simulations of lung deposition (from now on termed as in silico modeling) 14 
at the stability test times with the novel combined formulated samples and compare these results 15 
with the in vitro aerodynamic results. 16 
 17 
2. Materials and methods 18 
2.1. Materials 19 
Micronized ciprofloxacin hydrochloride (μCIP) (D50: 5.09 μm), was kindly provided by Teva 20 
Pharmaceutical Works Ltd. (Debrecen, Hungary). Lactose monohydrate, Inhalac® 70 (IH 70) 21 
(D50: 215.00 μm) was obtained from MEGGLE Group (Wasserburg, Germany) and used as a 22 
carrier. Magnesium stearate (MgSt) (D50: 6.92 μm) was applied as a surface modifier (Sigma-23 
Aldrich, Budapest, Hungary) of the carrier [34]. Sodium stearate (NaSt) (Alfa Aesar, Heysham, 24 
United Kingdom) was used for a surface modifier of the co-spray dried particles [35]. Both of 1 
them are frequently applied moisture protective agents [36,37]. 2 
2.2. Methods 3 
2.2.1. Preparation of the samples 4 
For the stability test, we again produced the samples which had been examined in our previous 5 
work [18]. We prepared carrier-based, carrier-free, and novel combined formulated DPI 6 
systems. Table 1. contains the w/w % compositions of these samples. The carrier-based 7 
formulation (µCIP+IH70) – as a reference [38] – was prepared with mixing in 1:10 [39] mass 8 
ratio of the drug and carrier by turbula blending (Turbula System Schatz; Willy A. Bachofen 9 
AG Maschinenfabrik, Basel, Switzerland) for half an hour at 60 rpm [36]. The carrier-free 10 
formulation (CIP_0.5NaSt_spd) was produced from a solution with co-spray-drying of CIP and 11 
NaSt. Firstly, we made a 1.5 w/v % aqueous solution using CIP and the alcoholic solution 12 
containing 0.0175 w/v % NaSt at 30 °C. Then the two solutions were mixed in the 7: 3 ratio. 13 
Büchi B-191 apparatus (Mini Spray Dryer, Büchi, Switzerland) was applied for the co-spray-14 
drying procedure with the following parameters: inlet heating temperature, 130 °C, outlet 15 
heating temperature, 78 °C, aspirator capacity, 75 %, pressured air flow, 600 L/min, feed pump 16 
rate, 5 %. So the solid formulation contained 99.5 w/w % of CIP and 0.5 w/w % of NaSt. The 17 
novel combined formulated sample (CIP_0.5NaSt_spd+IH70_MgSt) combined the two above-18 
mentioned preparation methods supplemented with carrier surface treatment. The surface 19 
modification of IH 70 carrier was made by 2.0 w/w % of MgSt (according to the literature 20 
background and the applied marketed concentration [40,41] ) with turbula mixing for 4 h [34]. 21 
Then we prepared co-spray-dried particles as described in the carrier-free section and these 22 
particles were blended with a surface smoothed carrier in the 1:10 mass ratio with a turbula 23 
mixer at 60 rpm for 30 min. 24 
Table 1. Composition of the DPI formulations containing the applied concentration of 1 
excipients. 2 
2.2.2. Investigation of the stability of samples 3 
Stability tests were performed in Binder KBF 240 (Binder GmbH Tuttlingen, Germany) 4 
equipment, with a constant-climate chamber. An electronically controlled APT.line™ line 5 
preheating chamber and refrigerating system ensured temperature accuracy and reproducibility 6 
of the results in the temperature range between 10 and 70 ºC and the RH (Relative Humidity) 7 
range between 10 and 80 %. The stability test was performed at 25 ± 2 ºC with 50± 5 % RH 8 
(room conditions). Samples were stored in hard gelatine capsules (size 3) (Capsugel, Germany) 9 
in open containers; the duration of storage was 1 month. Sampling was carried out after 0 and 10 
10 days, and 1 month. 11 
2.2.3. X-ray powder diffraction (XRPD) 12 
XRPD was implemented in order to determine the crystalline form of the produced DPI 13 
formulations. The powder samples were loaded in contact with a plane quartz glass sample slide 14 
with an etched square, and measured with a slit detector Cu K λI radiation (λ = 1.5406 Å) source. 15 
Settings were as follows: the samples were scanned at 40 kV and 40 mA and the angular range 16 
was 3°–40° 2θ, at a step time of 0.1 s/step and a step size of 0.01°. 17 
2.2.4. FT-IR analysis 18 
An FT-IR apparatus was used before and after storage for the study of the interaction between 19 
the components and test the chemical stability of the materials. FT-IR spectra were recorded 20 
with a Bio-Rad Digilab Division FTS- 65A/896 FTIR spectrometer (Bio-Rad Digilab Division 21 
FTS-65A/869, Philadelphia, PA, United States) between 4000 and 400 cm-1, at an optical 22 
resolution of 4 cm-1. Thermo Scientific GRAMS/AI Suite software (Thermo Fisher Sciencific 23 
Inc., Waltham, United States) was used for the spectral analysis. The sample, with a CIP content 24 
of 0.5 mg, was mixed with 150 mg of dry KBr in an agate mortar, and the mixture was then 1 
compressed into a disc at 10 t. Each disc was scanned 128 times at a resolution of 2 cm-1 over 2 
the wavenumber region 4000-400 cm-1. 3 
2.2.5. Thermogravimetry (TG) 4 
Residual solvent content was investigated by TG-DTA with a Mettler Toledo TG 821e thermal 5 
analysis system with the STARe thermal analysis program V9.1 (Mettler Inc., Schwerzenbach, 6 
Switzerland) under a constant flow of dry nitrogen gas flow of 100 mL min-1. Aluminium pans 7 
were applied for the samples and the reference. Scans were recorded at a constant heating rate 8 
(10 °C min-1) up to 350 °C. The TG-DTA oven was pre-equilibrated at room temperature and 9 
each sample (ranging between 12 and 20 mg) was weighed as fast as possible in order to 10 
minimize moisture uptake or release from the sample. The mass losses were recorded, and the 11 
moisture contents [% wet basis] were evaluated from the normalized scans, the actual mass is 12 
divided by the initial mass. The loss of water basically occurred between 5 and 110 °C, and the 13 
higher temperature was used for the determination of bound water. 14 
2.2.6. Interparticle interactions 15 
Contact angle () was determined by using a Dataphysics OCA 20 apparatus (Dataphysics Inc. 16 
GmbH, Germany), from which we could count some of the correlations (see below). The 17 
pastilles were pressed from 0.10 g of the samples with 1 ton compression force (Perkin Elmer 18 
hydraulic press, Waltham, USA). Six pastilles were made of each sample. Of this, three were 19 
dripped with distilled water (as a polar liquid) and the other three pastilles were dripped with 20 
diiodomethane (as dispersion liquid). Thus, we obtained the contact angle of the two different 21 
fluids by three parallel tests per sample. At the same time as the dropping, we made a recording 22 
by using the device in 1-25 seconds time interval, so it was possible to detect and determine the 23 
change of the contact angle. The surface free energy (  of the samples was calculated based 24 
on the Wu-equation. This energy consists of two parts: a disperse part ( ) and a polar part (1 
), thereby . The surface tension of the liquids is known in literature 2 
): distilled water γp=50.2 mN/m, γd=22.6 mN/m and diiodomethane γp=1.8 3 
mN/m, γd=49 mN/m [42]. In the Wu-equation, therefore, there are only two unknowns: the 4 
disperse ( ) and the polar component ( ) of the solids tested, which can already be expressed. 5 
The Wu-equation is the following [43]: 6 
 7 
where  = contact angle; γ = surface free energy; s = solid phase; l = liquid phase; d = 8 
dispersion component; p = polar component 9 
Cohesion work (Wc) corresponds to twice the surface free energy [44]: 10 
Wc = 2*  11 
The adhesion work (Wadh) that can be interpreted between the two different materials 12 
(represented by numbers 1 and 2) can be determined from the dispersion ( ) and polar 13 
component ( ) values calculated for the material in the present formula  and , and it 14 
equals [44]: 15 
 16 
Several models are known for the determination of adhesion force (Fadh). In our present work 17 
we used Derjaguin's approach, which is commonly used in pharmaceutical technology [43]: 18 
 19 
where RA and RB are the radius of the A and B particles, between which adhesive interactions 1 
were measured. R was defined as half of D [0.5], which was determined in the particle size 2 
analysis of the used raw materials. 3 
The spreading coefficient (S12) shows the spreadability of one material (1) on the surface of the 4 
other material (2). Conversely, it can be calculated. It is used in two-component systems to 5 
characterize distribution. This coefficient is a dimensionless number. Spreading is favorable if 6 
the result is a positive value, and the higher the number. In this case, the spreading of the drug 7 
particles can be characterized on the surface of the carrier. The coefficient or reverse case can 8 
be calculated using the following equations [43,44]: 9 
 10 
 11 
where γd is the disperse part of surface free energy and γp is the polar part of surface free energy 12 
and γ is the total surface free energy of the components whose is spread on the other component. 13 
2.2.7. Particle size analysis 14 
The particle size distribution of the used active ingredients, excipients, and the formulations 15 
before and after storage from the dry dispersion unit were also measured by laser light scattering 16 
(Malvern Mastersizer Scirocco 2000, Malvern Instruments Ltd., Worcestershire, UK). 17 
Approximately 0.5 g of composition was loaded into a feeder tray. In the dry analysis method, 18 
the air was used as the dispersion agent for the sample particles. The dispersion air pressure 19 
was adjusted to 2.0 bars in order to determine whether particle attrition had occurred. At least 20 
three repeated measurements were made on each sample, and the mean value was calculated. 1 
Particle size distribution was characterized by the D[0.1], D[0.5], and D[0.9] values. 2 
2.2.8. Scanning electron microscopy (SEM) 3 
The morphology of the samples was investigated by scanning electron microscopy – SEM – 4 
(Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). The samples were coated with an 5 
electrically conductive coating (Bio-Rad SC 502, VG Microtech, Uckfield, UK). The air 6 
pressure was 1.3-13.0 MPa. In brief, the samples were sputter coated with gold–palladium (90 7 
seconds) under an argon atmosphere applying a gold sputter module in a high vacuum 8 
evaporator and the samples were studied using SEM set at 10-15 kV. 9 
2.2.9. Aerodynamic assessment with the Andersen Cascade Impactor Model 10 
The in vitro aerodynamic properties of the formulations were tested with the Andersen Cascade 11 
Impactor (ACI) (Copley Scientific Ltd., Nottingham, UK), which is a most commonly used to 12 
characterize the aerosolization performance of the inhaled DPIs. This corresponds to the United 13 
States Pharmacopeia and Ph. Eur. 2.9.18 requirements [26,45]. The vacuum pump (High-14 
capacity Pump Model HCP5, Critical Flow Controller Model TPK, Copley Scientific Ltd., 15 
Nottingham, UK) provided 28.3 L/min flow rate and a corresponding ACI assembly was 16 
applied to that flow. The actual flow rate through the impactor was detected with the mass flow 17 
meter (Flow Meter Model DFM 2000, Copley Scientific Ltd., Nottingham, UK). Before each 18 
test, to prevent particle bounce the ACI collection plates were coated with a surfactant (Span 19 
80 + cyclohexane solution; 1 + 99 w/w %), so repeated inhalation into the cascade impactor 20 
was possible. In our experiments, the samples were measured in a hard gelatin capsule 21 
(transparent, size 3, Capsugel, Germany). The drug content of the formulations was detected 22 
with an UV/Vis spectrophotometer (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, 23 
UK). The amounts charged into the capsules were determined so that the CIP content per sample 24 
was 10 mg [12]. This mass corresponds to the tenth of the CIP oral dose [27]. During our testing, 1 
Breezhaler® (Novartis) inhaler was used. The filled capsule was placed in this inhaler and then 2 
with the help of the needles of the appliance the capsule was punched with a definite movement. 3 
Because of the big amount of carrier lactose, in the cases of carrier-based and novel 4 
formulations, to apply the same amount of CIP (10 mg), we used 2 capsules per one dose 5 
application. The DPI device, the mouthpiece, the induction port, the eight plates of the impactor, 6 
and the filter were washed with distilled water and the CIP concentration was quantified with 7 
an UV/Vis spectrophotometer (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, UK) 8 
at 276 nm. Knowing the amount of the active ingredient in the device and in the parts of the 9 
impactor, the emitted fraction (EF), fine particle fraction (FPF) and mass median aerodynamic 10 
diameter (MMAD) were determined. FPF expresses the fraction of particles having an 11 
aerodynamic diameter less than 5 micron, these particles are likely to be deposited in the lungs. 12 
However, more and more publications express the percentage of particles below 3 microns as 13 
they are most likely to reach the deep lung [46,47]. MMAD is defined as the diameter of the 14 
particles deposited in the impactor for which 50% w/w of particles have a lower diameter and 15 
50% w/w have a higher diameter [48]. EF was expressed as the percentage of the drug found in 16 
the ACI (except the drug found in the capsules and device). Only the drug concentration was 17 
determined by analytical method. Therefore we can use this data by the calculation of emitted 18 
fraction. 19 
2.2.10. In silico characterization 20 
For the estimation of the amount of drug depositing in different anatomical regions of the 21 
airways (upper airways, lungs), the most up-to-date version of the Stochastic Lung Model 22 
(SLM) of Koblinger and Hofmann (1990) [49] was applied. Indeed, the impactor measurements 23 
can demonstrate the repeatability of formulation batches and reveal the aerodynamic properties 24 
(size, size distribution) of the sample. However, these data can be used as predictors of airway 25 
deposition as well, with the mentioning that impactor measurements cannot provide exact 1 
airway deposition values like the scintigraphic studies. However, computer models validated 2 
against scintigraphic measurements (like the one presented in this study) are able to estimate 3 
the deposited amount quite exactly. Deposition in the extrathoracic region was calculated based 4 
on the formulas derived by Cheng (2003) [50]. Particles which were not filtered out by the 5 
upper airways were tracked in stochastic tracheobronchial geometry. Airway lengths, 6 
diameters, bifurcation angles and gravity angles were selected from statistical distributions 7 
based on the morphometric database of Raabe et al. (1976) [51]. The architecture of the acinar 8 
airways relied on the data published by Haefeli-Bleuer and Weibel (1988) [52]. Inertial 9 
impaction and gravitational settling were considered as deposition mechanisms in both the 10 
bronchial and acinar parts of the airways. Particle size distributions determined by Andersen 11 
Cascade impactor as part of this work were used as inputs for the deposition simulations. In 12 
addition, the breathing parameters of a patient when inhaling through Breezhaler® were used as 13 
modeling inputs (inhaled air volume: 1.7 L, inhalation time: 3.2 s, breath-hold time after the 14 
inhalation: 5 s and 10 s, exhalation time: 3 s). The breathing parameters were adopted from the 15 
work of Colthorpe et al. (2015) and corresponded to a female patient with moderate COPD. 16 
The exact deposition values naturally depend on the disease type and degree of severity, 17 
however, the main conclusions of the present work would not be affected. The simulated high 18 
lung deposition values associated with the formulation would even increase for patients with 19 
less impaired lung function. These data correspond to the breathing parameter values measured 20 
by Colthorpe et al. (2013) [53]. This patient was selected because his/her inhalation parameter 21 
values yield an average flow rate value very close to 30 L/min, which was applied in the present 22 
impactor measurements. 23 
2.2.11. Statistical analyses 24 
The statistical analyses were performed with the Social Science Statistics Online web page 1 
2019. For the stability assessment using t-test calculation at 0.05 significance level and one-2 
tailed hypothesis (Social Science Statistics Online). All reported data are means ± S.D of three 3 
parallel measurements (n=3). 4 
 5 
3. Results and discussion 6 
3.1. Structural characterization 7 
Figure 1. Structural investigation of the formulations by XRPD before and after storage 8 
XRPD makes it possible to track the structural changes of the DPI samples during storage, 9 
which can be analyzed if the XRPD patterns of CIP and of the used excipients are known. 10 
Specifically, the characteristic of the solid state form of the active ingredient particles could be 11 
very important, since the crystalline form or amorphous form could present results in 12 
morphological differences and influences the interparticle interactions, thus affecting the 13 
aerodynamic results. According to the XRPD diffractograms (Figure 1.A), we can determine 14 
the characteristic peaks of the starting materials. These are the following: 12.8, 16.8 and 20.0 15 
2Theta degree of IH 70; 8.23, 9.25, 19.22, 26.39 and 29.16 2Theta degree of CIP; 3.8, 5.5 16 
2Theta degree of MgSt and 4.0, 6.0 2Theta degree of NaSt. All of these materials are crystalline. 17 
We can conclude that the surface modification of IH 70 with 2 w/w% MgSt did not cause any 18 
change in the XRPD pattern, thus not causing any structural change either. 19 
In the case of samples (Figure 1.B) it can be concluded that CIP could be found mainly in 20 
amorphous form in the CIP_0.5NaSt_spd, however the characteristic peaks of NaSt and CIP 21 
(with small intensity) could be found on the curve before storage, but after 1 month complete 22 
recrystallization is seen and the CIP XRPD pattern in the above figure is almost identical. 23 
However, based on the peaks at 8.23, 9.25 and 26.39 2Theta degree, we can make statements 24 
about carrier-based formulations as well. Thus for µCIP+IH70 it can be established that the 1 
initial crystalline nature of the active ingredient particles remains, and there is no change. In the 2 
case of freshly prepared CIP_0.5NaSt_spd+IH70_MgSt, the active ingredient particles were 3 
mainly amorphous similarly to CIP_0.5NaSt_spd, but after 1 month a substantial amount of 4 
crystal structure change is not apparent on the XRPD pattern, which indicates that 5 
CIP_0.5NaSt_spd+IH70_MgSt has greater structural stability relative to the latter composition. 6 
Therefore the crystalline peaks correspond to IH 70. 7 
According to the FT-IR analyses, the FT-IR spectra of the raw components and the prepared 8 
samples before and after storage compared with each other (Figures are not presented in the 9 
article). We concluded that no chemical decomposition was presumable. 10 
3.2. Thermogravimetry (TG) 11 
Table 2. Residual solvent content in samples. 12 
The determination of thermogravimetric residual solvent content for DPIs is of key importance 13 
in tracking the stability of samples. By increased residual solvent content decreased stability is 14 
presumable. An increase in this value may indicate a decrease in stability. Moisture sorption 15 
can cause the agglomeration of the particles; can modify interparticle interactions and influence 16 
drug dispersion; de-agglomeration, which affects the lung deposition results [54]. The 17 
percentages resulting from residual solvent content (Table 2.) from our measurements are 18 
realistic for DPIs [55]. We have found that the residual solvent content has increased after 1 19 
month for the µCip +IH70 and CIP_0.5NaSt_spd formulations. For example, it provides an 20 
explanation for the recrystallization of the latter composition. In the case of the novel combined 21 
formulated DPI (CIP_0.5NaSt_spd+IH70_MgSt) residual solvent content did not change, and 22 
it decreased slightly. The present of MgSt caused the moisture resistance of the composition 23 
and this phenomenon already described in the international literature [36] has been confirmed 24 
by us. It has also been found that the moisture resistance of the DPI composition is improved 1 
by the use of MgSt as an excipient. The largest residual solvent content change was observed 2 
for the CIP_0.5NaSt_spd formulation, in contrast, there was no significant change in the novel 3 
combined formulated DPI (CIP_0.5NaSt_spd+IH70_MgSt), which also contains 4 
CIP_0.5NaSt_spd. 5 
3.3. Interparticle interactions 6 
Table 3. Cohesion, adhesion values and spreading coefficient of the formulations. 7 
Interparticle interactions have already been studied in our previous work [18]. Cohesive work 8 
(Wc) in the carrier-free formulations (between the drug particles), furthermore, adhesive work 9 
(Wadh) and force (Fadh) in the carrier-based formulations (between drug and carrier particles) 10 
are correlated with the in vitro lung deposition results. The studies were performed after a period 11 
of 1 month storage, as shown in Table 3., the Fadh of µCIP+IH70 did not change, this means 12 
that the active ingredient particles continue to adhere strongly to the carrier, so a low FPF value 13 
is expected after 1 month, too. In the case of CIP_0.5NaSt_spd, Wc increased substantially, 14 
approaching the value of fully crystalline µCIP, resulting from recrystallization and residual 15 
solvent content growth that contribute to interparticle interaction change. As cohesion between 16 
the active ingredient particles is increased, they can aggregate more easily. For the novel 17 
combined formulated DPI (CIP_0.5NaSt_spd+IH70_MgSt), Fadh did not increase greatly, still 18 
not reaching the value of adhesion of µCIP+IH70, and the spreading coefficient (S21) remained 19 
in the negative range left. The latter suggests that a vectored drug position can still be assumed 20 
on the surface of the carrier, it is not completely covered with it. All this - encountered with 21 
CIP_0.5NaSt_spd+IH70_MgSt - can be explained by the structure testing and the residual 22 
solvent content experience. Thus, it is expected that the FPF value will be outstanding in the in 23 
vitro lung deposition assay after 1 month. 24 
3.4. Particle size analysis and scanning electron microscopy (SEM) 1 
Table 4. Morphology and particle size distribution of the formulations during the 2 
storage. 3 
The study of particle size distribution and the morphology of the DPI samples also has great 4 
importance during storage. According to existing literature, it can be said that the range of 1-5 5 
microns is the optimal drug particle size for appropriate lung deposition. Particles greater than 6 
5 microns are deposited in the throat and trachea with great probability and most of the 7 
submicron particles are exhaled [56]. Furthermore, in terms of morphology, it can be stated that 8 
spherical particles produced by spray-drying have a low contact area; homogeneous particle 9 
size distribution and these result in a higher FPF than in the case of mechanically micronized 10 
drugs [57]. Table 4 shows the results of SEM and laser light scattering. We can conclude that 11 
the (average) diameters measured by Malvern and SEM are in correlation. We focused on the 12 
active ingredient particles on SEM. The average particle size of the drug particles remained in 13 
the range of 1-5 microns nevertheless, it increased for all formulations during the stability test, 14 
which can somewhat reduce the lung deposition results. In the case of the µCIP+IH70 15 
formulation, no aggregation or morphological changes can be observed after 1 month. After 1 16 
month, the CIP_0.5NaSt_spd formulation shows the recrystallization and aggregation of the 17 
particles, which is also indicated by XRPD; residual solvent content; cohesion results and the 18 
significantly increased D [0.9] value. In contrast, there is no significant morphological change 19 
which would refer to recrystallization; and there is no aggregation even in SEM images in terms 20 
of the CIP_0.5NaSt_spd+IH70_MgSt formulation containing the spray-dried drug particles – 21 
of the same method as the sample mentioned above – on the surface modified carrier. We 22 
collected the D [0.5] values of the drug and the carrier by the carrier-based formulations using 23 
the bimodal distribution curves (see table below). However, D [0.1] and D [0.9] could be 24 
determined only for the formulations. We concluded that the size of CIP in µCIP+IH70 sample 25 
changed from 4.92 µm to 5.34 µm and the size of IH70 changed from 180.03 µm to 186.66 µm. 1 
Furthermore, the size of CIP _0.5NaSt_spd in CIP_0.5NaSt_spd+IH70_MgSt sample changed 2 
from 2.27 µm to 2.57 µm and the size of IH70_MgSt changed from 171.12 µm to 179.45 µm. 3 
If we compare the change in D [0.5] size of CIP_0.5NaSt_spd and of CIP _0.5NaSt_spd in 4 
CIP_0.5NaSt_spd+IH70_MgSt we can see that in the combined formulation the size changing 5 
was smaller than by the carrier-free sample. Therefore, in the case of the novel combined 6 
formulated formulations, high FPF values are still expected in terms of in vitro lung deposition. 7 
3.5. Aerodynamic assessment with the Andersen Cascade Impactor Model 8 
Table 5. FPF value of microparticles before and after storage. 9 
Table 6. EF and MMAD values of microparticles before and after storage. 10 
In vitro lung modeling with the Andersen Cascade Impactor results in FPF, MMAD and EF 11 
(Table 5., 6.) that have been defined in the Method section. The quantities of the samples were 12 
chosen after drug content determination, where the measured drug content was between 82 and 13 
93% compared to the theoretical drug content. We concluded that these values didn’t change 14 
after the storage also. The lung deposition values (FPF) were based on the results of physical 15 
examinations (XRPD, residual solvent content, interparticle interactions, morphology and 16 
particle size). Thus, after 1 month of storage, the novel combined formulated DPI 17 
(CIP_0.5NaSt_spd+IH70_MgSt) had the best FPF results, outstandingly high FPF <3 µm, 18 
which indicates a high deep-lung deposition (approximately three times the FPF <3 µm value 19 
of µCIP+IH70 and double of CIP_0.5NaSt_spd). This is due to the fact that there is no 20 
significant change in the structure and residual solvent content of this composition (in fact, the 21 
latter changed favorably), thus the adhesion values did not increase substantially and its 22 
morphology did not change the active ingredient particles. All this leads to a reduction in the 23 
lung deposition result compared to the freshly made formulation. In contrast, CIP_0.5NaSt_spd 24 
(it should be noted again that there is such an active ingredient particle in the novel combined 1 
formulated formulation, and also that these particles passed down into the lung in both 2 
formulations, but scattered from the carrier at the CIP_0.5NaSt_spd+IH70_MgSt) 3 
recrystallized, the residual solvent content increased and these led to an increase in cohesion 4 
work, its morphology became disadvantageous and aggregated. Thus, FPF <3 µm and FPF <5 5 
µm values almost fell by half after 1 month of storage. For μCIP + IH70 (reference sample), it 6 
has been found that the FPF <5 µm value remained about 20%, which is typical for most of the 7 
marketed formulations [26]. The decrease in FPF, which is characteristic of all formulations, 8 
can be correlated with the established average particle size increase of CIP _0.5NaSt_spd in the 9 
formulation. Concerning MMAD, we found that the MMAD value is inversely proportional to 10 
the FPF values and only CIP_0.5NaSt_spd+IH70_MgSt indicates that the particle size 11 
measured with laser light scattering and the MMAD calculated with in vitro pulmonary 12 
modeling are also around the ideal 1-5 micron range. The EF for the formulations containing 13 
the carrier (μCIP + IH70 and CIP_0.5NaSt_spd+IH70_MgSt) was very high and was not 14 
considerably altered during storage, however, this value of the carrier-free formulation 15 
(CIP_0.5NaSt_spd) increased, presumably due to structural change (hence the morphology 16 
change), so the interparticle interactions between the capsule wall and the particles were 17 
modified favourably. 18 
3.6. In silico assessment of particle deposition 19 
Figure 2. In silico lung modeling results of the novel combined formulated DPI, SD < ± 20 
3% (ET: extrathoracic airways, LUNG: bronchial and acinar parts, EXH: exhalation 21 
fraction). 22 
The in vitro lung modeling we used is entirely suitable for comparing the aerodynamic 23 
properties of the DPI formulations. At the same time, the results from the measurements with 24 
Andersen Cascade Impactor are well complemented with the in silico lung modeling, which 25 
takes into account parameters other than the above-mentioned results. As the in vitro 1 
investigations revealed, the novel formulation is characterized by very high and nearly emitted 2 
fraction value which remained nearly constant over time (Table 5). The fine particle fractions 3 
remained also high after storage (Table 6). The MMAD values remained in the favourable 4 
aerodynamic range regarding deposition (especially the MMAD value after 10 days of storage). 5 
All these characteristics predicted high lung deposition values not only of the fresh sample, but 6 
also after storage. All these predictions were confirmed by the in silico results depicted in Figure 7 
2. In addition, the validated numerical models simulate the in vivo conditions using real-8 
spirometric data, so they give a more realistic picture of the behavior patterns during inhalation 9 
as they take real clinical data into consideration. We can type in individualized data based on 10 
age; sex; type and severity of lung disease. It should be noted, however, that in the above-11 
mentioned two pulmonary models, the expressed lung deposition values have different 12 
interpretations (this is the explanation for the different percentages of FPF values by in vitro 13 
and LUNG values by in silico), but it is absolutely possible to compare the tendencies of the 14 
formulations and the two methods support each other. The in silico measurements were carried 15 
out in Section 2.2.9. In our previous work, the in vitro and in silico results of fresh samples 16 
(μCIP + IH70; CIP_0.5NaSt_spd; CIP_0.5NaSt_spd + IH70_MgSt) showed the same tendency 17 
[18]. The in silico results of the formulation with the best in-vitro pulmonary deposition values 18 
(CIP_0.5NaSt_spd + IH70_MgSt) after 10 days and 1 month of storage is shown in Figure 2 19 
with 5 s and 10 s as breath-hold time. The figure reveals that, as predicted by the in vitro 20 
characterization, this formulation yielded high simulated lung deposition fraction values. At the 21 
same time, the extrathoracic dose fraction remained below 30% after storage (even decreased 22 
by storage). This is a significant improvement compared to the other two formulations. The 23 
freshly produced CIP_0 .5NaSt_spd (carrier-free) had approximately 40 %, upper airway 24 
deposition, while μCIP + IH70 (carrier-based) yielded a 50 % value [18]. The exhaled dose 25 
fraction was approximately 20% and decreased by the increase of breath-hold time, while the 1 
extrathoracic dose fraction proved to be insensitive to the length of breath-hold. Lung 2 
deposition was higher for longer breath-hold indicating that the optimization of the inhalation 3 
technique can contribute to further improving the pulmonary deposition of the novel combined 4 
formulated DPI and to reducing the exhaled amount. 5 
Conclusion 6 
Stability tests were carried out on carrier-based, carrier-free, and novel combined formulated 7 
DPI sample (CIP_0.5NaSt_spd + IH70_MgSt), containing antibiotic. After the storage, the 8 
novel combined formulation presented advantageous aerodynamic results thanks to the 9 
technological steps and the compositions. This sample has the most beneficial MMAD (2,5 µm) 10 
and best FPF (<5 µm; 50 %) results after 1 month, followed by the carrier-free, and the worst 11 
results are shown by the carrier-based formulations (as concluded by, for example, high residual 12 
solvent content, high Wadh and aerodynamically unfavourable morphology). From the results 13 
of the physicochemical examinations, we can conclude that in the case of the novel combined 14 
formulated sample (CIP_0.5NaSt_spd + IH70_MgSt), an appreciable amount of crystal 15 
structure change is not apparent on the XRPD pattern, the residual solvent content was slight 16 
due to the MgSt and NaSt content. As regards interparticle interactions, it can be stated that the 17 
adhesion force of μCIP + IH70 has remained high during the stability test, while in the case of 18 
CIP_0.5NaSt_spd, cohesion work has increased considerably, indicating that this formulation 19 
is easier to aggregate, which is also supported by electron microscopic images, and the 20 
recrystallization on the images could be seen. Based on these results, CIP_0.5NaSt_spd + 21 
IH70_MgSt introduced suitable stability, therefore required physicochemical properties 22 
compare with the carrier-free formulation (where the preparation of the contained drug particles 23 
was the same). However, after 1 month of storage, by the EF values, a good percentage of all 24 
the three formulations was observed, The novel combined formulated sample with the best in 25 
vitro lung deposition results was chosen for in silico lung modeling, and it was in correlation 1 
with the in vitro aerodynamic results. It should be emphasized that this sample had an 2 
extrathoracic dose fraction value below 30 % even after one month, while the freshly produced 3 
samples from the other two samples also had worse results. Finally, it can be stated that a novel 4 
combined formulated DPI formulation with favourable physicochemical characters after 1 5 
month storage, resulted improved in vitro-in silico aerodynamic properties which could be the 6 
reason to get stable formulation for the further development of DPIs. 7 
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Table 1. Compositions of the DPI formulations containing the applied concentration of 1 
excipients. 2 
Products CIP [w/w %] NaSt [w/w %] IH 70 [w/w %] MgSt [w/w %] 
µCIP+IH70 9.09 - 90.91 - 
CIP_0.5NaSt_spd 99.50 0.50 - - 
CIP_0.5NaSt_spd 
+IH70_MgSt 
9.045 0.045 88.91 2.00 
 3 
Table 2. Residual solvent content in the samples. 4 
Products 
Residual solvent content (%) 
Before storage 1 month 
µCIP+IH70 0.492 ± 0.009 0.518 ± 0.006 
CIP_0.5NaSt_spd 0.175 ± 0.002 0.218 ± 0.110 
CIP_0.5NaSt_spd+IH70_MgSt 0.500 ± 0.005 0.490 ± 0.003 
 5 
Table 3. Cohesion, adhesion values and spreading coefficient of the preparations. 6 
Products 
Wc 
[mN/m] 
Wadh 
[mN/m] 
Fadh 
[mN] 
S21 
Before 
storage 
1 month 
Before 
storage 
1 
month 
Before 
storage 
1  
month 
Before 
storage 
1  
month 
µCIP 
161.60 
±0.26 
160.06 
 ±0.66 
‒ ‒ ‒ ‒ ‒ ‒ 
µCIP+IH70 ‒ ‒ 
108.26 
± 0.56 
107.39 
± 0.77 
1.690 *10-3 
± 0.09*10-3 
1.677 *10-3 
± 0.15*10-3 
1.64  
± 0.08 
2.38 
 ± 0.13 
CIP_0.5NaSt_spd 
123.26 ± 
0.89 
144.74  
± 1.13 
‒ ‒ ‒ ‒ ‒ ‒ 
CIP_0.5NaSt_spd 
+IH70_MgSt 
‒ ‒ 
72.57  
± 1.26 
81.81 
 ± 0.98 
0.504 *10-3 
± 0.11*10-3 
0.593 *10-3 
± 0.07*10-3 
‒19.06 
± 0.23 
-49.1 
 ± 0.36 
 7 
  8 
Table 4. Morphology and particle size distribution of the formulations during the 1 
storage. 2 
 3 
Table 5. FPF value of microparticles before and after storage. 4 
Products 
Before 
storage 
10 days 1 month 
µCIP+IH70 
FPF <5 µm [%] 23.30 ± 0.23 17.57 ± 0.45 15.55 ± 0.36 
FPF <3 µm [%] 11.88 ± 0.20 8.67 ± 0.36 7.83 ± 0.18 
CIP_0.5NaSt_spd 
FPF <5 µm [%] 54.27 ± 2.75 39.41 ± 1.91 30.22 ± 1.82 
FPF <3 µm [%] 27.14 ± 2.38 17.43 ± 0.96 12.72 ± 1.66 
CIP_0.5NaSt_spd+IH70_MgSt 
FPF <5 µm [%] 63.75 ± 1.21 57.36 ± 2.21 47.12 ± 0.78 
FPF <3 µm [%] 39.22 ± 0.74 33.56 ± 0.96 26.52 ± 1.12 
 5 
  6 
Products Before storage 10 days 1 month 
µCIP+IH70 
   
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
15.034 
± 0.16 
156.028 
± 1.85 
198.152 
± 1.73 
25.550  
± 0.26 
170.366 
± 0.86 
257.835 
± 1.19 
31.846 
± 0.22 
180.277 
± 1.81 
285.720 
± 1.36 
CIP_0.5NaSt_spd 
   
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
1.208 
± 0.05 
2.364 
 ± 0.11 
4.556 
 ± 0.09 
1.494  
± 0.02 
2.466 
 ± 0.06 
5.321 
 ± 0.04 
1.608 
± 0.07 
2.981 
 ± 0.12 
23.123 
 ± 0.08 
CIP_0.5NaSt_spd 
+IH70_MgSt 
   
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
D [0.1] 
(µm) 
D [0.5] 
(µm) 
D [0.9] 
(µm) 
3.245 
± 0.12 
128.763 
± 0.78 
194.180 
± 0.63 
4.513  
± 0.08 
137.106 
± 1.15 
221.555 
± 1.26 
5.830 
± 0.02 
158.440 
± 1.78 
278.396 
± 1.36 
Table 6. EF and MMAD values of microparticles before and after storage. 1 
Products 
Before 
storage 
10 days 1 month 
µCIP+IH70 
EF [%] 96.92 ± 0.11 95.56 ± 0.22 96.52 ± 0.45 
MMAD 
[µm] 
7.98 ± 0.10  10.02 ± 0.15 11.40 ± 0.23 
CIP_0.5NaSt_spd 
EF [%] 76.99 ± 3.32 92.23 ± 0.21 92.32 ± 0.19 
MMAD 
[µm] 
4.14 ± 0.18 5.48 ± 0.28 6.54 ± 0.05 
CIP_0.5NaSt_spd+IH70_MgSt 
EF [%] 90.45 ± 1.80 90.65 ± 0.32 89.46 ± 1.12 
MMAD 
[µm] 
3.47 ± 0.02 4.03 ± 0.19 5.47 ± 0.35 
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Figure 2 8 
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